GlassScriptPhysician profile
Brian P Ragona
NPI 1992701015
$1,168.45
in general payments reported to CMS, 2019-2025
18 companies · $36.97 in 2025
The $36.97 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $266 · 2021: $28.78 · 2022: $209 · 2023: $424 · 2024: $203 · 2025: $36.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $266.47 | 2020 | |
| Lilly USA, LLC | $168.25 | 2022-2025 | Mounjaro |
| Abbvie INC. | $146.00 | 2023-2024 | |
| Pfizer INC. | $89.12 | 2023-2024 | |
| Dexcom, INC. | $61.94 | 2022-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $55.34 | 2022-2023 | Eliquis, Camzyos |
| Abbott Laboratories | $54.84 | 2021-2023 | Freestyle Libre 3 |
| Indivior INC. | $46.57 | 2022-2023 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $43.29 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $42.92 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $38.46 | 2022 | |
| Glaxosmithkline, LLC. | $37.06 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $32.19 | 2022 | |
| Exact Sciences Corporation | $19.51 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $19.32 | 2023 | Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $17.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.04 | 2023 | Quviviq |
| Braeburn INC. | $14.05 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ragona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.